GLP-1 medications like semaglutide are metabolized primarily by the liver and broken down into smaller compounds, meaning they do not depend on kidney clearance the way many other diabetes drugs do
This is a preview of subscription content, access via your institution Access options Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription 27,99 / 30 days cancel any time Subscribe to this journal Receive 12 print issues and online access 251,40 per year only 20,95 per issue Rent or buy this article Prices vary by article type from$1.95 to$39.95 Prices may be subject to local taxes which are calculated during checkout Subjects References Lincoff, A
Risks vs benefits for SGLT2 inhibitor medications
To view or add a comment, sign in How Canada assesses and values medications has real consequences for patients and families
Patients with psoriasis vulgaris frequently experience systemic comorbidities, including cardiovascular and metabolic diseases, and approximately 30% develop psoriatic arthritis (PsA), which requires treatment